11/21
08:38 am
atos
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research [Yahoo! Finance]
Low
Report
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research [Yahoo! Finance]
11/21
08:30 am
atos
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
Low
Report
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research
11/20
08:30 am
atos
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
Medium
Report
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium
11/19
12:09 am
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/13
01:45 pm
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at HC Wainwright from $6.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at HC Wainwright from $6.00 to $7.00. They now have a "buy" rating on the stock.
11/12
08:30 am
atos
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
11/8
11:07 pm
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/5
08:44 am
atos
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development [Yahoo! Finance]
Low
Report
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development [Yahoo! Finance]
11/5
08:30 am
atos
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
Low
Report
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
11/4
06:30 am
atos
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:
Medium
Report
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:
10/31
10:42 am
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
10/31
08:15 am
atos
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer
Low
Report
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer
10/28
11:40 am
atos
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? [Yahoo! Finance]
Low
Report
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? [Yahoo! Finance]
10/25
11:05 pm
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
10/21
08:30 am
atos
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer
Low
Report
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer
10/14
05:15 pm
atos
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit [Yahoo! Finance]
Low
Report
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit [Yahoo! Finance]
10/14
05:08 pm
atos
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit
Low
Report
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit
10/1
08:30 am
atos
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum
Medium
Report
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum
9/19
10:59 am
atos
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Low
Report
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
9/11
08:02 am
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $6.25 to $6.50. They now have a "buy" rating on the stock.
Medium
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $6.25 to $6.50. They now have a "buy" rating on the stock.
9/10
08:30 am
atos
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer
Medium
Report
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer
9/3
08:30 am
atos
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Medium
Report
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
8/28
08:30 am
atos
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
Neutral
Report
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen